Genprex (NASDAQ:GNPX) Sees Large Growth in Short Interest

Genprex (NASDAQ:GNPX) was the recipient of a large growth in short interest during the month of August. As of August 14th, there was short interest totaling 62,590 shares, a growth of 69.7% from the July 30th total of 36,884 shares. Based on an average trading volume of 391,029 shares, the days-to-cover ratio is presently 0.2 days. Currently, 7.7% of the company’s stock are sold short.

Analysts Set New Price Targets

A number of equities analysts recently commented on GNPX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genprex in a research note on Friday, July 17th. Wall Street Zen upgraded Genprex from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Genprex Price Performance

NASDAQ:GNPX opened at $3.55 on Wednesday. The firm has a market capitalization of $2.91 million, a P/E ratio of -0.03 and a beta of -0.88. Genprex has a 12-month low of $3.46 and a 12-month high of $1,210.00. The business has a 50 day simple moving average of $7.38 and a 200 day simple moving average of $21.13.

Genprex (NASDAQ:GNPX) last posted its earnings results on Friday, August 14th. The company reported ($9.40) earnings per share (EPS) for the quarter.

Institutional Trading of Genprex

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Mayflower Financial Advisors LLC acquired a new stake in Genprex in the 1st quarter valued at about $36,000. Manchester Financial Inc. acquired a new stake in Genprex during the 1st quarter worth about $36,000. Finally, Susquehanna International Group LLP raised its holdings in shares of Genprex by 11.7% during the third quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock valued at $58,000 after acquiring an additional 35,661 shares during the period. Institutional investors own 14.05% of the company’s stock.

About Genprex

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.